期刊文献+

首发广泛性焦虑障碍患者血浆脑源性神经营养因子水平的动态观察

Dynamic level observation of brain-derived neurotrophic factor in patients with first-episode generalized anxiety disorder
原文传递
导出
摘要 目的了解首发广泛性焦虑障碍患者血浆脑源性神经营养因子(BDNF)变化规律。方法测定34例于2007年1—12月在湖州市第三人民医院就诊的广泛性焦虑障碍首发患者基线、帕罗西汀治疗6周末血浆脑源性神经营养因子水平,同时评定相应时点汉密尔顿抑郁量表(HAMD)、汉密尔顿焦虑量表(HAMA)分值,并与31名正常人(对照组)比较。结果首发广泛性焦虑障碍患者基线BDNF(80±51)ng/L,较对照组高,与基线HAMA、HAMD评分无显著相关性。治疗6周末(70±49)ng/L与HAMA、HAMD评分均存在显著相关性(分别为r=0.4,P=0;r=0.4,P=0)。6周末有效(含痊愈)组和无效组BDNF分别为(60±42)ng/L和(83±55)ng/L,无效组和对照组比较差异有统计学意义;痊愈组和非痊愈组BDNF水平分别为(59±52)ng/L和(73±49)ng/L,非痊愈组和对照组比较差异有统计学意义。结论首发GAD患者血浆BDNF水平在治疗前较正常人高,治疗达到痊愈的患者可能会降到正常水平。 Objective To examine the changing pattern of brain-derived neurotrophic factor (BDNF) in the patients with first-episode generalized anxiety disorder (GAD). Methods The levels of plasma BDNF and the Hamilton anxiety scale ( HAMA ) and Hamilton depression scale ( HAMD ) scores were measured in 34 patients with first-episode GAD recruited from our hospital between January and December 2007. At baseline and Week 6, they were treated by paroxetine and compared with 31 healthy participants in the control group. Results The baseline level of BDNF [ (80 -51 ) ng/L] in the patients with first-episode GAD was higher than that in the control group and had no significant correlation with HAMA and HAMD scores. But at Week 6, the level of BDNF [ (70 ±49) ng/L] had significant correlations with HAMA and HAMD scores ( r = 0.4, P = 0 and r = 0.4, P = 0 respectively). At Week 6, the levels of BDNF in the response group (including remission group) and ineffective group were (60±42) ng/L and (83 ± 55 ) ng/L respectively. And there was significant difference in the levels of BDNF between the ineffective and control groups. The levels of BDNF in the remission and non-remission groups were (59±52) ng/L and (73 ± 49 ) ng/L respectively. And there was significant difference in the levels of BDNF between the non-remission and control groups. Conclusion The pre-treatment levels of plasma BDNF in the patients with first-episode GAD are higher than those of healthy counterparts. But normal levels may be restored if the patients are cured.
出处 《中华医学杂志》 CAS CSCD 北大核心 2011年第41期2939-2941,共3页 National Medical Journal of China
基金 浙江省医药卫生科技计划项目(2005A095)
关键词 焦虑症 脑源性神经营养因子 治疗效果 Anxiety disorders Brain-derived neurotrophie factor Treatment outcome
  • 相关文献

参考文献9

  • 1Grant BF, Hasin DS, Stinson FS, et al. Prevalence, correlates,co-morbidity, and comparative disability of DSM-Ⅳ generalized anxiety disorder in the USA: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Psychol Med, 2005, 35:1747-1759.
  • 2Stahl SM. Stahl's essential psychopharmacology neuroscientific basis and practical applications. 3rd ed. New York: Cambridge University Press, 2008:732-756.
  • 3MacQueen GM, Ramakrishnan K, Croll SD, et al. Performance of heterozygous brain-derived neurotrophic factor knockout mice on behavioral analogues of anxiety, nociception, and depression. Behav Neurosci, 2001, 115 : 1145-1153.
  • 4Govindarajan A, Rao BS, Nair D, et al. Transgenic brain-derived neurotrophic factor expression causes both anxiogenic and antidepressant effects. Proc Natl Acad Sci U S A, 2006,103: 13208-13213.
  • 5Pandey SC, Zhang H, Roy A, et al. Central and medial amygdaloid brain-derived neurotrophic factor signaling plays a critical role in alcohol-drinking and anxiety-like behaviors. J Neurosci, 2006, 26:8320-8331.
  • 6Jockers-Scherubl MC, Zubraegel D, Baer T, et al. Nerve growth factor serum concentrations rise after successful cognitivebehavioural therapy of generalized anxiety disorder. Prog Neuropsychopharmacol Biol Psychiatry, 2007, 31:200-204.
  • 7Lee BH, Kim H, Park SH, et al. Decreased plasma BDNF level in depressive patients. J Affect Disord, 2007, 101: 239-244.
  • 8Yoshimura R, Mitoma M, Sugita A, et al. Effects of paroxetine or milnacipran on serum brain-derived neurotrophic factor in depressed patients. Prog Neuropsychopharmacol Biol Psychiatry, 2007, 31 : 1034-1037.
  • 9Martinowich K, Lu B. Interaction between BDNF and serotonin: role in mood disorders. Neuropsychopharmacology, 2008, 33 : 73 -83.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部